Hallmarks of response to immune checkpoint blockade

British Journal of Cancer

Volumn 117, Issue 1, 2017, Pages 1-7

  Cogdill, Alexandria P ^a   Andrews, Miles C ^a   Wargo, Jennifer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

checkpoint inhibitors; hallmarks; immunotherapy; precision medicine

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASM; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PERSONALIZED MEDICINE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PRECISION MEDICINE; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 85021453088     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.136     Document Type: Review

References (44)

1. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. (2012). The determinants of tumour immunogenicity. Nat Rev Cancer 12(4): 307-313.
2. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13): 5213-5219.
3. Chen DS, Mellman I. (2013). Oncology meets immunology: the cancerimmunity cycle. Immunity 39(1): 1-10.
4. Chen DS, Mellman I. (2017). Elements of cancer immunity and the cancerimmune set point. Nature 54.1(7637).: 321-330.
5. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. (2010). Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23): 9554-9561.
6. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, Validire P, Besse B, Mami-Chouaib F. (2015). CD8CD103 tumorinfiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 194(7): 3475-3486.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 31.3(5795).: 1960-1964.
8. Gopalakrishnan V, Spencer CS, Reuben A, Karpinets T, Hutchinson D, Hoffman K, Prieto PA, Tetzlaff MT, Lazar A, Davies MA, Gershenwald JE, Jenq RR, Hwu P, Sharma P, Allison JP, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. (2017). Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. 2017 ASCO-SITC Clinical Immuno-Oncology Symposium; Orlando, FL, USA. J Clin Oncol 35(suppl 7S): abstract 2.
9. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-Analysis. Lancet 37.0(9581).: 59-67.
10. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
11. Heninger E, Krueger TE, Lang JM. (2015). Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol 6: 29.
12. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm Jr MC, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2(7): 632-642.
13. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723.
14. Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M, Naka T, Ojima T, Ueda K, Hayata K, Nakamura Y, Yamaue H. (2011). Tumor-infiltrating CD4 Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 25(5): 1271-1277.
15. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128(4): 683-692.
16. Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, Sexton S, Hong CC, Gordon CJ, Abrams SI, Repasky EA. (2013). Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci USA 110(50): 20176-20181.
17. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. (2016). Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7: 10501.
18. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1): 23-34.
19. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26): 2509-2520.
20. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C. (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 35.1(6280).: 1463-1469.
21. Meehan K, Vella LJ. (2016). The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin Lab Sci 53(2): 121-131.
22. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. (2013). Increased frequency of ICOS CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4): 229-234.
23. Pardoll DM. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4): 252-264.
24. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18(6): 883-891.
25. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett Jr RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. (2016). Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2): 202-216.
26. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21): 2006-2017.
27. Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Zarour HM, Kefford R, Loboda A, Albright A, Kang SP, Ebbinghaus S, Yearley J, Murphy E, Nebozhyn M, Lunceford JK, McClanahan T, Ayers M, Daud A. (2015). Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature. 2015 ASCO Annual Meeting; Chicago, IL, USA. J Clin Oncol 33(suppl): abstr 3001.
28. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 34.8(6230).: 124-128.
29. Schreiber RD, Old LJ, Smyth MJ. (2011). Cancer immunoediting: integrating immunity?s roles in cancer suppression and promotion. Science 33.1(6024).: 1565-1570.
30. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4): 707-723.
31. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 35.0(6264).: 1084-1089.
32. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23): 2189-2199.
33. Spranger S, Bao R, Gajewski TF. (2015). Melanoma-intrinsic beta-catenin signalling prevents anti-Tumour immunity. Nature 52.3(7559).: 231-235.
34. Spranger S, Gajewski T. (2013). Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 1: 16.
35. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. (2013). Up-regulation of PD-L1, IDO, and T (regs) in the melanoma tumor microenvironment is driven by CD8() T cells. Sci Transl Med 5(200): 200ra116.
36. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. (2016). Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res 4(7): 563-568.
37. Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, No D, Gobourne A, Viale A, Dahi PB, Ponce DM, Barker JN, Giralt S, van den Brink M, Pamer EG. (2014). The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124(7): 1174-1182.
38. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 51.5(7528).: 568-571.
39. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 35.0(6257).: 207-211.
40. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Berard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 35.0(6264).: 1079-1084.
41. Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Canamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. (2016). Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 7: 12624.
42. Wherry EJ, Kurachi M. (2015). Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8): 486-499.
43. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB. (2013). Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4(11): 2067-2079.
44. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9): 819-829.